| アブストラクト | AIMS: Post-marketing surveillance has indicated potential suicide and self-injury signals in patients taking GLP-1RAs for weight management, despite no current psychiatric warnings in labeling. This study evaluated the association between GLP-1RAs and depression/suicide events using FDA Adverse Event Reporting System (FAERS) data. METHODS: A retrospective pharmacovigilance study analyzed FAERS data (2004-2024) using reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) analyses to evaluate depression and suicide/self-injury adverse events for liraglutide, semaglutide, and tirzepatide. RESULTS: Analysis included 8284 reports for liraglutide (n = 3022), 14,435 for semaglutide (n = 4233), and 15,597 for tirzepatide (n = 5722). Significant signals were identified only for semaglutide in both depression (ROR, 1.87; 95 % CI, 1.60-2.20) and suicide/self-injury events (ROR, 1.73; 95 % CI, 1.46-2.04). Effects were consistent across sex groups but most pronounced in ages 18-64. Post-weight management approval saw increased reporting, particularly in European and North American regions. Tirzepatide showed significantly lower mortality rates (0.26 %) compared to other agents. CONCLUSION: Findings identified significant depression and suicidality signals with semaglutide in weight management. For patients requiring weight reduction therapy, particularly those with psychiatric comorbidities, tirzepatide may represent a more appropriate choice based on its superior safety profile. |
|---|
| ジャーナル名 | Journal of affective disorders |
|---|
| Pubmed追加日 | 2025/6/17 |
|---|
| 投稿者 | Wang, Min; Yang, Zhiyun; Yan, Min; Liu, Shao; Xiao, Sa |
|---|
| 組織名 | Department of Pharmacy, Xiangya Hospital, Central South University, Changsha;410008, Hunan, China; National Clinical Research Center for Geriatric Disorders,;Xiangya Hospital, Central South University, Changsha 410008, Hunan, China; The;Hunan Institute of Pharmacy Practice and Clinical Research, Changsha 410008,;Hunan, China.;410008, Hunan, China.;Hunan, China. Electronic address: liushao999@csu.edu.cn.;Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South;China University of Technology, Foshan 528200, Guangdong, China. Electronic;address: xiaosa_sophia@163.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40523410/ |
|---|
